Vir Biotechnology Inc - Asset Resilience Ratio
Vir Biotechnology Inc (VIR) has an Asset Resilience Ratio of 19.14% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how Vir Biotechnology Inc's Asset Resilience Ratio has changed over time. Check Vir Biotechnology Inc PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Vir Biotechnology Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see VIR market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $196.28 Million | 19.14% |
| Total Liquid Assets | $196.28 Million | 19.14% |
Asset Resilience Insights
- Good Liquidity Position: Vir Biotechnology Inc maintains a healthy 19.14% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Vir Biotechnology Inc Industry Peers by Asset Resilience Ratio
Compare Vir Biotechnology Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Genfit S.A.
PA:GNFT |
Biotechnology | 64.01% |
|
Hyundai Bioscience Co. Ltd
KQ:048410 |
Biotechnology | 22.98% |
|
Altimmune Inc
NASDAQ:ALT |
Biotechnology | 82.06% |
|
Clarity Pharmaceuticals Ltd
AU:CU6 |
Biotechnology | 73.99% |
|
Jiangsu GDK Biotechnology Co Ltd
SHG:688670 |
Biotechnology | 9.82% |
Annual Asset Resilience Ratio for Vir Biotechnology Inc (2017–2025)
The table below shows the annual Asset Resilience Ratio data for Vir Biotechnology Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 22.81% | $228.75 Million | $1.00 Billion | -25.97pp |
| 2024-12-31 | 48.78% | $682.40 Million | $1.40 Billion | -17.96pp |
| 2023-12-31 | 66.74% | $1.28 Billion | $1.92 Billion | +11.31pp |
| 2022-12-31 | 55.44% | $1.55 Billion | $2.80 Billion | +37.00pp |
| 2021-12-31 | 18.44% | $360.33 Million | $1.95 Billion | -14.25pp |
| 2020-12-31 | 32.68% | $300.29 Million | $918.76 Million | -20.84pp |
| 2019-12-31 | 53.53% | $274.10 Million | $512.07 Million | +26.99pp |
| 2018-12-31 | 26.54% | $50.84 Million | $191.60 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $251.57 Million | -- |
About Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those ta… Read more